Screener
Ultragenyx Pharmaceutical RARE Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Ultragenyx Pharmaceutical in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: Ultragenyx Pharmaceutical’s 10-Q, filed August 5, 2026.
- Filed
- Aug 4, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333233
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Inventory | (7) | (1) |
| Prepaid expenses and other assets | 3 | (17) |
| Accounts payable, accrued, and other liabilities | (33) | (58) |
| Net cash used in operating activities | (294) | (275) |
| Investing activities: | ||
| Purchase of property, plant, and equipment | (2) | (4) |
| Purchase of marketable securities | (188) | (16) |
| Proceeds from sale of marketable securities | 38 | — |
Item 1. Financial Statements
FAQ
- What is Ultragenyx Pharmaceutical's operating cash flow?
- Ultragenyx Pharmaceutical (RARE) reported operating cash flow of -$97M in Q2 2026.
- How has Ultragenyx Pharmaceutical's operating cash flow changed year-over-year?
- Ultragenyx Pharmaceutical's operating cash flow increased by 11.0% year-over-year, from -$109M to -$97M.
- What is the long-term trend for Ultragenyx Pharmaceutical's operating cash flow?
- Over 4 years (2021 to 2025), Ultragenyx Pharmaceutical's operating cash flow has grown at a 8.3% compound annual growth rate (CAGR), from -$338.7M to -$466M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about Ultragenyx Pharmaceutical's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude